{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:34:58Z","timestamp":1740123298523,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010772","name":"Percy Falks Stiftelse f\u00f6r Forskning Betr\u00e4ffande Prostata- och Br\u00f6stcancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010772","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Br\u00f6stcancerf\u00f6rbundet"},{"DOI":"10.13039\/501100009752","name":"Futurum - Akademin f\u00f6r H\u00e4lsa och V\u00e5rd, Region J\u00f6nk\u00f6pings l\u00e4ns","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonden f\u00f6r Klinisk Cancerforskning i J\u00f6nk\u00f6ping"},{"DOI":"10.13039\/100014653","name":"Manchester NIHR Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to identify factors associated with progression-free survival (PFS) and overall survival (OS) in patients with metastatic breast cancer (MBC) treated with eribulin in a real-world setting, to improve information provision in those considering treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients treated with eribulin for MBC at The Christie NHS Foundation Trust, Manchester, UK, between August 2011 and December 2018 were included (<jats:italic>n<\/jats:italic>\u2009=\u2009439). Data were collected by retrospective review of medical records and electronic prescribing systems. Factors such as biological subtype, distant recurrence-free interval, previous lines of chemotherapy and the \u2018average duration of previous treatment lines\u2019 (ADPT) (calculated as: (date of initiation of eribulin\u2013date of MBC) \/ the number of previous treatment lines in the metastatic setting) were evaluated for prognostic impact using Cox proportional hazards regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the full cohort, the median PFS and OS were 4.1\u00a0months (95% CI 3.7\u20134.4) and 8.6\u00a0months (95% CI 7.4\u20139.8), respectively. Outcomes were significantly inferior for those with triple-negative breast cancer (TNBC) (<jats:italic>n<\/jats:italic>\u2009=\u200992); PFS<jats:sub>TNBC<\/jats:sub>: 2.4\u00a0months (95% CI 2.1\u20133.0), <jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.001 and OS<jats:sub>TNBC<\/jats:sub>: 5.4\u00a0months (95% CI 4.6\u20136.6), <jats:italic>p<\/jats:italic>\u2009=\u2009\u2009&lt;\u20090.001. ADPT was the only factor other than subtype significantly associated with PFS and OS. Longer ADPT was also significantly associated with PFS and OS in those with TNBC. For example, women in the lowest ADPT tertile (&lt;\u20095.0\u00a0months) achieved a median OS of only 4.3\u00a0months, whereas those in the upper ADPT tertile (&gt;\u20098.7\u00a0months) had a median OS of 12.1\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.004).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that the ADPT lines is an important factor when predicting the outcome with eribulin chemotherapy in a palliative setting and that quantitative guidance on the likely PFS and OS with treatment can be provided using ADPT. Validation in additional cohorts is warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10549-021-06438-7","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T11:03:21Z","timestamp":1638183801000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"191","author":[{"given":"Faye","family":"Coe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamini","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Adderley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Woodhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaheen","family":"Ayub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha","family":"Howell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5553-5323","authenticated-orcid":false,"given":"Maria","family":"Ekholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"issue":"6","key":"6438_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"Cancer J Clin"},{"issue":"12","key":"6438_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cort\u00e9s J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"issue":"9769","key":"6438_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, investigators E (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914\u2013923. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6","journal-title":"Lancet"},{"issue":"6","key":"6438_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594\u2013601. https:\/\/doi.org\/10.1200\/jco.2013.52.4892","journal-title":"J Clin Oncol"},{"issue":"3","key":"6438_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12282-017-0826-4","volume":"25","author":"X Pivot","year":"2018","unstructured":"Pivot X, Im SA, Guo M, Marm\u00e9 F (2018) Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 25(3):370\u2013374. https:\/\/doi.org\/10.1007\/s12282-017-0826-4","journal-title":"Breast Cancer"},{"issue":"3","key":"6438_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, Awada A (2014) Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 148(3):553\u2013561. https:\/\/doi.org\/10.1007\/s10549-014-3144-y","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"6438_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s10637-019-00890-5","volume":"38","author":"K Inoue","year":"2020","unstructured":"Inoue K, Takahashi M, Mukai H, Yamanaka T, Egawa C, Sakata Y, Ikezawa H, Matsuoka T, Tsurutani J (2020) Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting. Invest New Drugs 38(5):1540\u20131549. https:\/\/doi.org\/10.1007\/s10637-019-00890-5","journal-title":"Invest New Drugs"},{"issue":"5","key":"6438_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7150\/jca.8748","volume":"5","author":"T Gamucci","year":"2014","unstructured":"Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P (2014) Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer 5(5):320\u2013327. https:\/\/doi.org\/10.7150\/jca.8748","journal-title":"J Cancer"},{"key":"6438_CR9","doi-asserted-by":"publisher","first-page":"175883592110302","DOI":"10.1177\/17588359211030210","volume":"13","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Xie N, Li W, Chen W, Lv Z, Zheng Y, Sun T, Liu J, Zhang J, Hu S, Wang Y, Gong C, Li Y, Xie Y, Ge R, Xu F, Wang B (2021) Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study. Ther Adv Med Oncol 13:17588359211030210. https:\/\/doi.org\/10.1177\/17588359211030210","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"6438_CR10","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s12325-020-01613-6","volume":"38","author":"SS Mougalian","year":"2021","unstructured":"Mougalian SS, Kish JK, Zhang J, Liassou D, Feinberg BA (2021) Effectiveness of eribulin in metastatic breast cancer: 10 years of real-world clinical experience in the United States. Adv Ther 38(5):2213\u20132225. https:\/\/doi.org\/10.1007\/s12325-020-01613-6","journal-title":"Adv Ther"},{"key":"6438_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.breast.2020.09.004","volume":"54","author":"MH Park","year":"2020","unstructured":"Park MH, Lee SJ, Noh WC, Jeon CW, Lee SW, Son GS, Moon BI, Lee JS, Kang SS, Suh YJ, Gwak G, Kim TH, Yoo YB, Kim HA, Kim MY, Kim JY, Jeong J (2020) A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK). Breast 54:121\u2013126. https:\/\/doi.org\/10.1016\/j.breast.2020.09.004","journal-title":"Breast"},{"issue":"12","key":"6438_CR12","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1002\/ijc.32402","volume":"145","author":"W Jacot","year":"2019","unstructured":"Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A (2019) Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. Int J Cancer 145(12):3359\u20133369. https:\/\/doi.org\/10.1002\/ijc.32402","journal-title":"Int J Cancer"},{"key":"6438_CR13","doi-asserted-by":"publisher","first-page":"175883591989575","DOI":"10.1177\/1758835919895755","volume":"11","author":"V Adamo","year":"2019","unstructured":"Adamo V, Ricciardi GRR, Giuffrida D, Scandurra G, Russo A, Blasi L, Spadaro P, Iacono C, Soto Parra HJ, Savarino A, Ferra\u00fa F, Zerilli F, Verderame F, Butera A, Santangelo C, Franchina V, Caruso M (2019) Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study. Ther Adv Med Oncol 11:1758835919895755. https:\/\/doi.org\/10.1177\/1758835919895755","journal-title":"Ther Adv Med Oncol"},{"key":"6438_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40064-016-1700-0","volume":"5","author":"O Garrone","year":"2016","unstructured":"Garrone O, Montemurro F, Saggia C, La Verde N, Vandone AM, Airoldi M, De Conciliis E, Donadio M, Lucio F, Polimeni MA, Oletti MV, Giacobino A, Merlano MC (2016) Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life. Springerplus 5:59. https:\/\/doi.org\/10.1186\/s40064-016-1700-0","journal-title":"Springerplus"},{"issue":"4","key":"6438_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cort\u00e9s J (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530. https:\/\/doi.org\/10.1016\/s1470-2045(19)30863-0","journal-title":"Lancet Oncol"},{"issue":"7","key":"6438_CR16","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/tbj.13686","volume":"26","author":"J Cortes","year":"2020","unstructured":"Cortes J, Twelves C (2020) Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. Breast J 26(7):1347\u20131351. https:\/\/doi.org\/10.1111\/tbj.13686","journal-title":"Breast J"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06438-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T14:05:18Z","timestamp":1644501918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6438"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06438-7","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"3 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any competing interests, financial and non-financial, in relation to the work described.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Service evaluation in England is exempt from ethics committee review (Health Research Authority Guidance; ). The project was approved by The Christie NHS Foundation Trust as a service evaluation (IRB Reference\u00a0Number 16\/1795).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}